The underwriters took up the option to buy another 2.7 million shares after the Pfizer and Gilead-backed oncology therapy developer's shares leapt substantially post-IPO.

Gradescope has paid an undisclosed amount to acquire schoolwork analysis software developer Turnitin, which had raised more than $5m from investors including Bloomberg.

Alibaba will merge its online food delivery subsidiary Ele.me with its local services spinoff Koubei, following earlier reports that SoftBank was joining Alibaba to invest about $3bn of funding in the new business.

Anaplan has raised close to $264m in its flotation on the New York Stock Exchange that provided exits for Salesforce and Workday.

UC Berkeley’s SkyDeck accelerator has secured an exit as schoolwork assessment technology developer Gradescope was acquired by Turnitin.

The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.

This is our data snapshot based on last month’s investment activity. 
The charts and tables have been generated by our data platform GCV Analytics.

The following is a snapshot of the data we have collected on investment activity over the past three months. To verify reported deals, we contact about 300 corporate investors each quarter – these comprise roughly 18% of the global CVCs we cover, but account for most of the deals that are made public.

The synthetic DNA technology developer, which counts Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux, has filed to raise up to $86.3m.

GSK is the second largest shareholder of gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.